Sandu Pharmaceuticals Limited held a Board of Directors meeting on 14th November 2026 from 4:00 PM to 6:40 PM. The board reviewed and approved the unaudited financial results for the quarter and half year ended 30th September 2026, prepared in compliance with Ind-AS.

The financial results were reviewed by the Audit Committee and accompanied by a Limited Review Report issued by M/s Dave & Dave Chartered Accountants, Mumbai (Firm Registration No. 102163W), the company's statutory auditors, pursuant to Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Financial Performance Highlights

Quarter Ended 30th September 2026 (Q2 FY27):

  • Revenue from operations: ₹1,762.11 lakhs
  • Other income: ₹8.71 lakhs
  • Total income: ₹1,770.82 lakhs
  • Profit before tax: ₹121.97 lakhs
  • Tax expense: ₹43.40 lakhs (Current tax: ₹29.39 lakhs, Deferred tax: ₹9.15 lakhs, Short/Excess tax provision: ₹4.86 lakhs)
  • Net profit: ₹78.57 lakhs
  • Basic EPS: ₹0.81
  • Diluted EPS: ₹0.81

Half Year Ended 30th September 2026 (H1 FY27):

  • Revenue from operations: ₹3,432.01 lakhs
  • Other income: ₹6.56 lakhs
  • Total income: ₹3,438.58 lakhs
  • Profit before tax: ₹265.54 lakhs
  • Tax expense: ₹88.93 lakhs (Current tax: ₹66.60 lakhs, Deferred tax: ₹9.15 lakhs, Short/Excess tax provision: ₹13.18 lakhs)
  • Net profit: ₹176.61 lakhs
  • Basic EPS: ₹1.83
  • Diluted EPS: ₹1.83

Comparative Performance (Q2 FY26):

  • Revenue from operations: ₹1,638.88 lakhs
  • Net profit: ₹35.76 lakhs
  • Basic EPS: ₹0.37

Balance Sheet Position (as at 30th September 2026)

  • Total assets: ₹5,717.67 lakhs
  • Equity share capital: ₹966.10 lakhs (face value ₹10 per share)
  • Other equity: ₹3,435.20 lakhs
  • Total equity: ₹4,401.30 lakhs
  • Non-current liabilities: ₹172.49 lakhs
  • Current liabilities: ₹1,143.88 lakhs

Cash Flow Statement (Half Year Ended 30th September 2026)

  • Net cash flow from operating activities: -₹209.98 lakhs
  • Net cash flow from investing activities: ₹40.32 lakhs
  • Net cash flow from financing activities: -₹106.84 lakhs
  • Net decrease in cash and cash equivalents: ₹276.50 lakhs
  • Cash and cash equivalents at period end: ₹314.27 lakhs

Significant Notes to Financial Statements

1. The financial results are prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013

2. The company operates in one business segment: "Ayurvedic Proprietary Medicines"

3. The results were reviewed by the Audit Committee and approved by the Board of Directors

4. Figures for the quarter ended 30th September 2026 are balancing figures between audited full-year figures and published year-to-date figures

5. Previous period figures have been reclassified/regrouped where necessary

Auditor's Review

M/s Dave & Dave Chartered Accountants issued a limited review report stating that nothing has come to their attention that causes them to believe the financial results contain any material misstatement or fail to disclose information required by Regulation 33 of SEBI LODR Regulations.

The unaudited financial results and limited review report are available on the company's website at www.sandu.in.